|
|
Article: FOSAMAX Continues to Help Build Bone Through 10 Years of Treatment, Study in New England Journal of Medicine Finds.
- Article from:
- Business Wire
- Article date:
- March 17, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
UPPER GWYNEDD, Pa.--(BUSINESS WIRE)--March 17, 2004
Longest Prospective Clinical Trial in the Treatment of Postmenopausal
Osteoporosis Shows FOSAMAX(R) Maintained Bone Mineral Density at All
Skeletal Sites Measured
In the longest prospective clinical trial ever conducted in the treatment of postmenopausal osteoporosis -- a chronic condition that can lead to bone loss and susceptibility to fractures -- researchers found that postmenopausal women taking FOSAMAX(R) (alendronate sodium) maintained or continued to experience increases in bone mineral density (BMD) at the hip and spine ...